Grant: Master's Award: Canada Graduate Scholarships
University of Ottawa
$17,500.00
Therapeutic Potential of a Novel Anti-Oxidant Compound, WN1316, for Glaucoma
FY 2022-23
Summary
Glaucoma, a group of progressive ocular neurodegenerative diseases, is one of the leading causes of irreversible blindness worldwide. It is characterized by the apoptotic death of retinal ganglion cells (RGCs) and their axons that comprise the optic nerve. RGCs are neurons that serve to relay visual information to processing centres in the brain. Most glaucoma therapies target the reduction of intraocular pressure (IOP) given that elevated IOP is the main risk factor for RGC death. However, it has been observed that RGC death persists despite the administration of these therapies, indicating that multiple mechanisms may be responsible for the progression of glaucoma. It is thus imperative that future treatment avenues target the other factors that are proposed to contribute to the pathology of the disease. Accumulating evidence suggests that oxidative stress is among the critical factors that are involved in glaucoma pathology. In this study, the potential of a novel antioxidant compound, WN1316, for the treatment of glaucoma will be assessed in a mouse magnetic microbead model of the disease. WN1316 has been shown to suppress cell death and neuroinflammation in other disease models by upregulating endogenous factors that are involved in suppressing apoptosis and oxidative stress, as well as by suppressing the activity of pathological neuroinflammatory agents. Moreover, WN1316 has high blood-brain barrier and blood-retina permeability, low toxicity, and high solubility, making it an ideal therapeutic agent. It is therefore expected that WN1316 will protect against glaucomatous vision loss by preventing RGC death.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
486250
Name
Pourang Leyla Katherine
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Therapeutic Potential of a Novel Anti-Oxidant Compound, WN1316, for Glaucoma
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antioxidant; Drug Therapy; Glaucoma; Intraocular Pressure; Mouse Model; Neurodegeneration; Optic Nerve; Oxidative Stress; Retinal Ganglion Cells; Vision Loss
Abstract
Glaucoma, a group of progressive ocular neurodegenerative diseases, is one of the leading causes of irreversible blindness worldwide. It is characterized by the apoptotic death of retinal ganglion cells (RGCs) and their axons that comprise the optic nerve. RGCs are neurons that serve to relay visual information to processing centres in the brain. Most glaucoma therapies target the reduction of intraocular pressure (IOP) given that elevated IOP is the main risk factor for RGC death. However, it has been observed that RGC death persists despite the administration of these therapies, indicating that multiple mechanisms may be responsible for the progression of glaucoma. It is thus imperative that future treatment avenues target the other factors that are proposed to contribute to the pathology of the disease. Accumulating evidence suggests that oxidative stress is among the critical factors that are involved in glaucoma pathology. In this study, the potential of a novel antioxidant compound, WN1316, for the treatment of glaucoma will be assessed in a mouse magnetic microbead model of the disease. WN1316 has been shown to suppress cell death and neuroinflammation in other disease models by upregulating endogenous factors that are involved in suppressing apoptosis and oxidative stress, as well as by suppressing the activity of pathological neuroinflammatory agents. Moreover, WN1316 has high blood-brain barrier and blood-retina permeability, low toxicity, and high solubility, making it an ideal therapeutic agent. It is therefore expected that WN1316 will protect against glaucomatous vision loss by preventing RGC death.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Pourang, Leyla Katherine
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~